Why AN2 Therapeutics, Inc.’s (ANTX) Stock Is Up 12.86%
As of Wednesday, August 12, AN2 Therapeutics, Inc.’s ANTX share price has surged by 12.86%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Commentary & Analysis
Why AN2 Therapeutics, Inc.’s (ANTX) Stock Is Up 7.87%
As of Thursday, July 30, AN2 Therapeutics, Inc.’s ANTX share price has surged by 7.87%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why AN2 Therapeutics, Inc.’s (ANTX) Stock Is Up 5.42%
As of Tuesday, July 21, AN2 Therapeutics, Inc.’s ANTX share price has surged by 5.42%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why AN2 Therapeutics, Inc.’s (ANTX) Stock Is Up 9.62%
As of Monday, July 20, AN2 Therapeutics, Inc.’s ANTX share price has surged by 9.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why AN2 Therapeutics, Inc.’s (ANTX) Stock Is Down 5.78%
As of Wednesday, July 15, AN2 Therapeutics, Inc.’s ANTX share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ANTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $202.3 | $601.3 | 27% |
|
| Shares Out (Mil) | 44.8 | 43.1 | 45% |
|
| Institutional Ownership | 90.8% | 83.7% | 59% |
|
| Float (Mil) | 21.4 | 45.1 | 30% |
|
| Beta | -0.99 | 0.73 | 1% |
|
| Avg Daily Volume (000s) | 206 | 300 | 45% |
|
| Price Change (52-week) |
318.8% | 64.3% | 99% |
|
| Growth | ANTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (20.9%) | (1.5%) | 19% |
|
| EPS (5yr) | 27.2% | 15.1% | 78 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 39.0% | (15.0%) | 90% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.200) | ($0.895) | ($0.800) | |
| Month Ago EPS | ($0.200) | ($0.895) | ($0.800) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.240) | ($0.960) | ($1.040) | |
| Year/Year Chg | 9.3% | (23.1%) | (29.6%) | |
| Financials | ANTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($36) | ($11) | 19% |
|
| EPS (TTM) | ($1.040) | ($0.700) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($6) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $5 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $159 | $524 | 24% |
|
| Valuation | ANTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.56 | 2.54 | 60% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ANTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 0.8% | na |
|
| ROA | (46.1%) | (22.5%) | 12% |
|
| ROE | (50.1%) | (21.8%) | 15% |
|
| Liabilities to Assets | 7.0% | 32.8% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
AN2 Therapeutics, Inc. did not pass any screens on 9/15/2026.
